Navigation Links
WuXi PharmaTech Announces Licensing Agreement for Patient-Derived Xenograft Models with Mayo Clinic's Center for Individualized Medicine

SHANGHAI, Nov. 4, 2013 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced a licensing agreement with Mayo Clinic's Center for Individualized Medicine to expand WuXi's collection of patient-derived xenograft (PDX) mouse models.  These models will support the cancer drug discovery and personalized medicine efforts of WuXi's global customers.

Under this agreement, WuXi has been granted an exclusive license for a panel of patient-derived xenograft models for prevailing cancers in Western countries that have been developed in connection with the center's research and patient care.  The Mayo collection supplements WuXi's unique and extensive Chinese PDX collection, which includes more than 500 Chinese patient-derived xenograft models, more than 220 of which have been deep-sequenced using whole exome sequencing at 100X.  By combining PDX models derived from cancer tissues of patients representing Chinese and Western ancestries, WuXi is creating a single platform to allow its global customers to select highly relevant models with a higher probability of success for testing targeted therapies.

"This agreement with the internationally renowned Mayo Clinic enables WuXi to provide the global research community with a unique single resource that will help advance cancer research through a more relevant and clinically directed approach," said Dr. Ge Li, Chairman and CEO of WuXi.  "We look forward to working with world-class organizations like Mayo Clinic to further strengthen our integrated, open-access R&D services platform, which enables anyone and any company to discover and develop new medicines for improved patient care."

"We are delighted to work with WuXi, an organization with a strong reputation and industry leadership, to make our PDX models broadly available to the global cancer research community," said Dr. Gianrico Farrugia, Director of Mayo Clinic's Center for Individualized Medicine. "We hope use of these models leads to more predictive approaches to the discovery and development of personalized cancer therapies for patients."

Mayo Clinic has a financial interest in the technology mentioned in this news release.  Revenue Mayo receives is used to support the clinic's not-for-profit mission in patient care, education and research.

About WuXi PharmaTech

As a research-driven and customer-focused company, WuXi PharmaTech (Cayman) Inc. provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.  WuXi AppTec is the name for the operating subsidiaries of WuXi PharmaTech.  For more information, please visit:

For more information, please contact:

Ronald Aldridge
Director of Investor Relations
WuXi PharmaTech

Aaron Shi
Associate Director of Corporate Communications
WuXi PharmaTech

SOURCE WuXi PharmaTech
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. featured expert Kevin Matras highlights: Core Laboratories NV, Invesco Ltd., Medtronic, Inc., Willbros Group Inc. and WuXi PharmaTech Inc.
2. WuXi PharmaTech Schedules First-Quarter 2013 Earnings Release
3. Breckenridge announces agreement with Aptalis Pharmatech to market Propranolol Hydrochloride Extended-Release Capsules
4. WuXi PharmaTech Receives Letter from AAALAC Commending Animal Care at Suzhou Toxicology Facility as "Exemplary"
5. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results, Share Repurchase Program
6. WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies
7. WuXi PharmaTech Schedules Fourth-Quarter 2012 Earnings Release
8. WuXi PharmaTech Presents the 2012 Life Science and Chemistry Awards
9. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2012 Annual General Meeting
10. WuXi PharmaTech Celebrates Dr. Joseph Vaccas Induction into American Chemical Societys Medicinal Chemistry Hall of Fame
11. WuXi PharmaTech and Open Monoclonal Technology Announce OmniRat(TM) Antibody Collaboration
Post Your Comments:
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
(Date:6/23/2016)... 2016 , , , WHEN: ... 2016 , , , , LOCATION: , , , Online, ... , , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global ... Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager ... pharmaceutical industry is witnessing an exceptional era. Several new demand spaces, ...
(Date:6/23/2016)... the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... Sandra ... ... Astellas is a pharmaceutical company ...
Breaking Medicine Technology:
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
Breaking Medicine News(10 mins):